Key result
PCOS is linked to ~96% higher CRP levels versus healthy controls, highlighting chronic low-grade inflammation.
Why the study?
The role of inflammatory mediators and their genetic mechanisms in the pathogenesis of chronic low-grade inflammation in PCOS is not fully elucidated.
Chronic low-grade inflammation and genetic polymorphisms in inflammatory mediators play a significant role in the pathogenesis and metabolic manifestations of PCOS.
Answers are grounded in this paper and cite their sources.
May inform PCOS inflammation assessment; leaves open whether targeting CRP alters outcomes.
Polycystic ovarian syndrome (PCOS) is an endocrine disorder affecting 5-10% of reproductive-age women. Hyperandrogenemia, which characterizes the syndrome, stimulates the maturation of adipocytes and favors central obesity. The linking hub between obesity and other metabolic manifestations of the syndrome seems to be chronic low-grade inflammation. We discuss the most reliable current data regarding the role of inflammatory mediators in PCOS, with particular focus on the genetic mechanisms implicated. C-reactive protein levels are 96% higher in PCOS patients than in healthy controls. Patients with the -308A polymorphism of the tumor necrosis factor-α gene have elevated androgens in comparison with carriers of the -308G. Interleukin 18 (IL-18) is elevated in lean patients, with a further rise in the presence of obesity and insulin resistance. Polymorphisms of the IL-1a, IL-1b and IL-6 genes have also been associated with PCOS. Plasminogen activator inhibitor-1 levels are positively associated with the syndrome, and carriers of the 4G allele of the 4G/5G polymorphism are at risk of developing PCOS. Other mediators discussed include adhesion molecules, osteoprotegerin, asymmetric dimethylarginine, homocysteine and advanced glycation end-products. The elucidation of the pathogenetic mechanisms implicated in PCOS and their connection with low-grade inflammation may in the future offer the opportunity for the formulation of novel therapeutic strategies and individualized therapy for these patients.
No takes yet. Share an insight, caveat, or question.
Deligeoroglou et al. (2012) conducted a review in Polycystic ovarian syndrome (PCOS). Inflammatory mediators vs. Healthy controls was evaluated. C-reactive protein levels are 96% higher in PCOS patients than in healthy controls, highlighting the role of chronic low-grade inflammation in the syndrome's pathogenesis.
Synapse has enriched 10 related papers. Consider them for comparative context: